To explore the potential role of HDAC6 as a therapeutically exploitable target in BC, a trastuzumab-resistant subclone of two HER2+ BC cell lines—one expressing HDAC6 at low levels (SKBR3) and one at high levels (BT474)—was established. This evidence concerns the gene HDAC6 and breast cancer.